AI in the development of vaccines for emerging and re-emerging diseases
Authors:
- Rita Elizabeth Velastegui-HernándezRVRita Elizabeth Velastegui-Hernández
- Verónica Gabriela Salinas-VelasteguiVSVerónica Gabriela Salinas-Velastegui
- Diana Catalina Velastegui-HernandezDVDiana Catalina Velastegui-Hernandez
- Estefania Araceli Reyes-RoseroEREstefania Araceli Reyes-Rosero
- Andrea Carolina Cevallos-TenedaACAndrea Carolina Cevallos-Teneda
- Andrea Alexandra Tufiño-AguilarATAndrea Alexandra Tufiño-Aguilar
- Fabricio Alejandro Vasquez de la BanderaFBFabricio Alejandro Vasquez de la Bandera
- Gabriela SandovalGSGabriela Sandoval
- Luis Felipe Contreras-VásquezLCLuis Felipe Contreras-Vásquez
- Luis Fabián Salazar-GarcésLSLuis Fabián Salazar-Garcés
Open Access
- 15 January 2025
- journal article
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 4, .1285
Abstract
Introduction: The integration of artificial intelligence (AI) into vaccine development has revolutionized traditional methodologies, significantly enhancing the speed, precision, and scalability of immunological research. Emerging and re-emerging infectious diseases, driven by zoonotic spillovers, antimicrobial resistance, and global environmental changes, pose substantial challenges. Addressing these requires innovative approaches, with AI playing a pivotal role in advancing immunological solutions.Development: AI applications in vaccinology include antigen detection, adjuvant optimization, and immune response simulation. Deep learning algorithms streamline the identification of immunogenic targets and conserved antigens, enabling vaccine development for highly mutable pathogens such as SARS-CoV-2, HIV, and influenza. Case studies demonstrate AI's transformative impact, including its role in the rapid creation of mRNA vaccines for COVID-19, identification of promising antigens for malaria, and enhanced efficacy of influenza vaccines through predictive modeling. However, challenges such as unequal access to technology, biases in data models, and ethical concerns regarding genomic data privacy persist. Recommendations to address these barriers include increasing data diversity, strengthening ethical frameworks, and investing in global infrastructure to democratize AI-driven innovations.Conclusions: AI's ability to reduce time and cost, improve vaccine precision, and enable personalized immunization strategies positions it as a cornerstone of modern vaccinology. With continued advancements and equitable implementation, AI holds the potential to reshape vaccine development, improve pandemic preparedness, and address longstanding public health disparities globally.Keywords
This publication has 156 references indexed in Scilit:
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscapeNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- A Review of Artificial Intelligence and Machine Learning for Vaccine Research2024
- Computational frameworks for zoonotic disease control in Society 5.0: opportunities, challenges and future research directionsAI & SOCIETY, 2024
- Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug developmentCPT: Pharmacometrics & Systems Pharmacology, 2024
- Introduction to Infectious Diseases2024
- Factors Contributing to the Emergence of Viral Diseases2023
- Epidemiology and Control: From Principles to Pandemics2022
- Current view on novel vaccine technologies to combat human infectious diseasesApplied Microbiology and Biotechnology, 2021
- Vaccine Distribution—Equity Left Behind?JAMA, 2021
- Computational Intelligence in Vaccine Design Against COVID-192020